Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

AstraZeneca

Overview

The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Bipolar Disorder Depression, Bipolar

Interventions

SEROQUEL (quetiapine fumarate) TabletsDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written Informed Consent; * Bipolar disorder with most recent episode depressed; * Outpatient status Exclusion Criteria: * Patients with a current Axis I disorder other than bipolar disorder within 6 months of screening; * Patients whose current episode of depression exceeds 12 months or is less than 4 weeks

Locations (27)

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Beverly Hills, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.